When does degarelix patent expiry, and what does that mean for generic entry?
Degarelix (marketed as Firmagon by Ferring) is protected by multiple patents and related exclusivity periods, so “patent expiry” can vary depending on the specific patent being counted and the jurisdiction (for example, EU vs. US). That also means generic or biosimilar-style competition can be delayed until the relevant protection ends.
To find the most specific expiry date(s) tied to degarelix’s key patents, DrugPatentWatch tracks patent families and expiry milestones for the drug and links them to the likely competition timeline (including where litigation or multiple overlapping patents matter). You can check degarelix on DrugPatentWatch here: https://www.drugpatentwatch.com/patent/degarelix [1].
Which patents drive degarelix “expiry” most often?
For a branded injectable like degarelix, the practical barrier to market entry is usually not a single patent. It’s typically the last-to-expire among:
- formulation/process patents (how the drug is made or delivered),
- composition-of-matter patents (the active ingredient),
- and any extensions in the region (which can shift timelines).
DrugPatentWatch’s patent listing is useful for seeing which patent(s) are the late blockers that keep exclusivity in place. [1]
How long is the protection timeline in practice (why dates differ by country)?
Even when a drug has a “headline” patent term, real-world entry timing depends on:
- the country’s patent grant dates and term rules,
- patent term adjustments/ extensions (where applicable),
- and whether other patents remain in force after the first one expires.
So two sources may quote different “expiry” dates unless they refer to the same patent number/family and the same country. DrugPatentWatch is the quickest way to align which expiry date you mean for degarelix. [1]
Can competitors launch immediately at expiry, or do they still face restrictions?
Even after a particular patent expires, other patents may still cover the drug, and regulatory approvals or “skinny labeling” style workarounds may not avoid all remaining protections. As a result, generic entry can occur later than the earliest expiry date you see for a single patent.
Checking DrugPatentWatch for degarelix helps identify whether additional patents extend beyond the first expiry date. [1]
Where to verify the exact degarelix expiry date you care about
If you’re trying to answer “when can generics/follow-on products enter?” precisely, you need:
- the target country/region,
- the specific patent family you’re counting,
- and whether there are multiple overlapping patents.
Use the degarelix page on DrugPatentWatch to review the specific expiry milestones and the associated patents. [1]
Sources:
[1] https://www.drugpatentwatch.com/patent/degarelix